FDA records linked by MedtechLedger identify Diagnostica Stago, Inc. as the applicant on K260214, a premarket notification for STA® - Liquid Anti-Xa received on January 23, 2026 and decided substantially equivalent on September 24, 2026 under product code KFF, with a Special clearance type and a Summary statement. The same firm name appears as recalling firm in a separate device enforcement record. The company's own U.S. site describes Diagnostica Stago, Inc. as the U.S. subsidiary of Diagnostica Stago, S.A.S. France and the exclusive U.S. provider of the Diagnostica Stago Hemostasis product lines. [1][2][6]
Documented U.S. regulatory activity
The supplied collection holds one linked record, a 510(k) with a substantially equivalent decision, and the record sample contains that same single entry. The sample is therefore not a subset of a larger cited set, and the counts describe this filing snapshot rather than total company activity. K260214 lists the advisory committee as Hematology and the device classification as Class II under regulation number 864.7525, with the device name given as Assay, Heparin. [1]
An earlier decision summary for K111822, submitted by Diagnostica Stago Inc., covers clearance of a new device with heparin as the measurand and a chromogenic assay as the test type. That document lists the proprietary and established names STA®-Liquid Anti-Xa, STA®-Multi Hep Calibrator, STA®-Quality NHF/UFH and STA®-Quality HBPM/LMWH, and cites regulation sections 864.7525, 864.5425 and 862.1150 across product codes KFF, GGN and JIS. [4]
Product line and assay technology
The manufacturer's anticoagulant brochure describes the chromogenic anti-Xa principle in which Factor Xa is added in excess and residual Factor Xa hydrolyzes a chromogenic substrate, producing coloration. The same brochure lists anticoagulant agents by name, including fondaparinux, rivaroxaban, apixaban and edoxaban, alongside antithrombin. A Stago product page states that STA - Liquid Anti-Xa is used for the quantitative determination of anti-Xa activity and refers readers to the instructions for use. [5][7]
The K111822 decision summary records an acceptance criterion of less than 0.25 IU/mL relative to an un-spiked sample and reports maximum tolerated concentrations, without further detail in the available excerpt. The 2026 clearance record identifies the device as STA® - Liquid Anti-Xa and does not itself describe assay performance. [1][4]
Recall record for a protein S reagent
A Class II voluntary firm-initiated recall, Z-3047-2026, covers STA Staclot Protein S, model/catalog number 00746, reagent lot 273074, described as a qualitative and quantitative factor deficiency test. The stated reason is a positive drift in QC values within the reagent's stated 4-hour onboard stability period. The record lists 5,220 units, e-mail as the initial firm notification, a recall initiation date of July 29, 2026, a center classification date of August 28, 2026 and a report date of September 9, 2026, with status Ongoing. [2]
Distribution is described as U.S. nationwide across the states and territory of NJ, NY, VA, PA, FL, AL, GA, TN, OH, IL, MO, NE, TX, CO, UT, CA and PR. The record does not state clinical outcomes or the number of affected patients. [2]
Corporate identity and scope
Stago's U.S. website states that the Diagnostica Stago, Inc. head office is in Parsippany and that the firm is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States, with coagulation instruments and reagent kits for research and routine analysis. The same page identifies Diagnostica Stago, Inc. as the U.S. subsidiary of Diagnostica Stago, S.A.S. France. FDA filing addresses in the cited records also list Parsippany, NJ, but a filing address is not treated here as a verified headquarters. [1][2][6]
A CLIA search result for document number CR260178 returns one result without visible detail in the available excerpt, so its relationship to this firm is unknown. The manufacturer's product page lists Stago Group specialty brands including Agro-Bio, BioCytex, Synapse, Tcoag, Thrombinoscope and HemoSonics, and notes that its inter-laboratory comparison business is ISO/IEC 17043 accredited. [3][7]




